血清人附睾分泌蛋白4对子宫内膜癌的诊断价值：一项系统评价与Meta分析

Diagnostic value of serum human epididymal secretory protein 4 for endometrial cancer: a systematic review and meta analysis.

作者信息

Yuan Jie, Xu Chen, Liu Chunyong, Yan Ruiling

机构信息

Department of Obstetrics and Gynecology, the First Affiliated Hospital of Jinan University, Guangzhou, 510630, Guangdong Province, China.

Department of Science and Education, Guangzhou Chest Hospital, Guangzhou, 510095, Guangdong Province, China.

出版信息

Discov Oncol. 2024 Sep 27;15(1):498. doi: 10.1007/s12672-024-01234-3.

DOI:10.1007/s12672-024-01234-3

PMID:39331203

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11436588/

Abstract

OBJECTIVE

The diagnostic value of serum human epididymal secretory protein 4 (HE4) for endometrial cancer (EC) was assessed via evidence-based medicine (EBM) and systematic review (SR) methodologies.

METHODS

The Cochrane Library, PubMed, Web of Science, Embase, CBM, CNKI, and Wan Fang databases were searched up to April 1st, 2024, to identify relevant literature. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool was utilized to evaluate the quality of the selected studies. The meta-analysis was conducted via RevMan 5.3, STATA 16.1, and Meta-disc software.

RESULTS

A total of 22 studies comprising 9036 cases (3776 cases in the case group and 5260 cases in the control group) were included. The results revealed that HE4 exhibited a pooled sensitivity of 0.59 [95% CI (0.53, 0.64)], specificity of 0.93 [95% CI (0.88, 0.96)], positive likelihood ratio (PLR) of 6.87 [95% CI (4.57, 10.33)], negative likelihood ratio (NLR) of 0.46 [95% CI (0.39, 0.54)], diagnostic odds ratio (DOR) of 14.36 [95% CI (9.37, 21.17)], and area under the receiver operating characteristic curve (AUC) of 0.78 [95% CI (0.75, 0.82)].

CONCLUSIONS

Serum HE4 demonstrates high specificity and moderate sensitivity for diagnosing EC, thus serving as a valuable biomarker for clinicians either alone or in conjunction with other tumour markers.

摘要

目的

通过循证医学（EBM）和系统评价（SR）方法评估血清人附睾分泌蛋白4（HE4）对子宫内膜癌（EC）的诊断价值。

方法

检索截至2024年4月1日的Cochrane图书馆、PubMed、Web of Science、Embase、CBM、CNKI和万方数据库，以识别相关文献。使用诊断准确性研究质量评估2（QUADAS - 2）工具评估所选研究的质量。通过RevMan 5.3、STATA 16.1和Meta - disc软件进行荟萃分析。

结果

共纳入22项研究，包括9036例病例（病例组3776例，对照组5260例）。结果显示，HE4的合并敏感性为0.59 [95%可信区间（CI）（0.53，0.64）]，特异性为0.93 [95% CI（0.88，0.96）]，阳性似然比（PLR）为6.87 [95% CI（4.57，10.33）]，阴性似然比（NLR）为0.46 [95% CI（0.39，0.54）]，诊断比值比（DOR）为14.36 [95% CI（9.37，21.17）]，以及受试者工作特征曲线下面积（AUC）为0.78 [95% CI（0.75，0.82）]。